Skip to main content

Table 1 Patient characteristics

From: Impaired kidney function at ED admission: a comparison of bleeding complications of patients with different oral anticoagulants

 

DOAC (n=158)

VKA (n=419)

Total (n=577)

p

Demographic data

 Sex, male [n (%)]

88 (55.7)

239 (57.0)

327 (56.7)

0.771

 Age, [median (IQR)]

79.0 (72-83)

79.0 (70-85)

79.0 (71-84)

0.774

Renal function

 Creatinine, μmol/L [median (IQR)]

132 (110-162)

141 (118-193)

138 (115-182)

0.002

 GFR group, [n (%)]

  45-59 mL/min

61 (38.6)

131 (31.3)

192 (33.3)

 

  30-44 mL/min

65 (41.1)

147 (35.1)

212 (36.7)

 

  15-29 mL/min

31 (19.6)

110 (26.3)

141 (24.4)

 

  <15 mL/min

1 (0.6)

31 (7.4)

32 (5.5)

0.002

Comorbidity

 Charlson Comorbidity Index, [median (IQR)]

5 (4-7)

5 (4-7)

5 (4-7)

0.144

 Diabetes, [n (%)]

45 (28.5)

123 (29.4)

168 (29.1)

0.837

 Liver insufficiency, [n (%)]

9 (5.7)

9 (2.1)

18 (3.1)

0.029

 Arterial hypertension, [n (%)]

109 (69.0)

306 (73.0)

415 (71.9)

0.335

 Polypharmacy, [n (%)]

138 (87.3)

353 (84.2)

491 (85.1)

0.352

  1. Abbreviations: DOAC direct oral anticoagulants, GFR glomerular filtration rate, IQR Interquartile range, VKA Vitamin-K antagonist